Victor I.
- Country
- Belgium
- Department
- Cardiology
Research Overview
- Phase 3 Randomized Double-Blind Study of NTLA-2001 Efficacy and Safety in Transthyretin Amyloidosis with Cardiomyopathy Patients
- TRITON-CM: A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nucresiran in Patients with Transthyretin-Mediated Amyloidosis with Cardiomyopathy (ATTR amyloidosis with cardiomyopathy)
Data & Insights
Has run more than one trial at 34 of 122 partner sites.
Specializations
Cardiovascular Research
Specializes in investigating innovative treatments for cardiac muscle diseases, with particular emphasis on cardiomyopathy and its various manifestations.
- Cardiac Muscle Disorders
- Cardiovascular Mortality Prevention
- Heart Disease Management
Focuses on evaluating therapeutic interventions for heart-related conditions.
Amyloidosis Studies
Conducts research in transthyretin amyloidosis, specifically investigating its cardiac manifestations and potential therapeutic approaches.
- Protein Misfolding Disorders
- Amyloid Deposition
- Cardiac Amyloidosis
Explores advanced treatment options for amyloid-related cardiac conditions.
Therapeutic Development
Investigates novel therapeutic compounds for cardiovascular conditions, with expertise in evaluating treatments for rare cardiac disorders.
- Clinical Efficacy Assessment
- Cardiovascular Events
- Treatment Outcomes
Evaluates innovative approaches to treating complex cardiac conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.